Article thumbnail

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

By K Dredge, J B Marriott, C D Macdonald, H-W Man, R Chen, G W Muller, D Stirling and A G Dalgleish

Abstract

The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties. Second generation thalidomide analogues are distinct compounds with enhanced therapeutic potential. Although these compounds are beginning to enter trials for the treatment of cancer there is very little information regarding the anti-angiogenic activity of these clinically relevant compounds. Furthermore, it is not known how the various immunomodulatory activities of these compounds relate to anti-angiogenic activity. In this study we assessed the anti-angiogenic activity of compounds from both IMiD™ and SelCID™ classes of analogues using a novel in vitro multicellular human assay system and the established rat aorta assay. Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide. The anti-angiogenic potency of the analogues was not related to inhibition of endothelial cell proliferation, nor their TNF-α/PDE type 4 inhibitory properties. However, anti-migratory effects in vitro and inhibition of tumour growth in vivo was observed with the analogue IMiD-1 (clinically known as REVIMID™). Our results show that anti-angiogenic activity spans both currently defined classes of thalidomide analogue and is not related to their previously described immunomodulatory properties. Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting

Topics: Experimental Therapeutics
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2376196
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1998). Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.
  2. (2000). Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy.